Statement of Ownership (sc 13g)
February 12 2021 - 01:03PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13G
(Rule
13d-102)
Under
the Securities Exchange Act of 1934
IMMATICS
N.V.
(Name
of Issuer)
Ordinary
shares, nominal value €0.01 per share
(Title
of Class of Securities)
N44445109
(CUSIP
Number)
December
31, 2020
(Date
of Event Which Requires Filing of This Statement)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
|
*
|
The
remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in
a prior cover page.
|
The
information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
|
|
|
|
|
CUSIP
NO. N44445109
|
|
13
G
|
|
Page
2 of 14 Pages
|
1.
|
|
Name
of Reporting Persons
dievini
Hopp BioTech holding GmbH & Co. KG
|
2.
|
|
Check
the Appropriate Box if a Member of a Group (See Instructions)
(a) ☐ (b) ☐
(1)
|
3.
|
|
SEC
USE ONLY
|
4.
|
|
Citizenship
or Place of Organization
Germany
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
|
|
5.
|
|
Sole
Voting Power
0
ordinary shares
|
|
6.
|
|
Shared
Voting Power
16,476,073
ordinary shares (2)
|
|
7.
|
|
Sole
Dispositive Power
0
ordinary shares
|
|
8.
|
|
Shared
Dispositive Power
16,476,073
ordinary shares (2)
|
9.
|
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
16,476,073
ordinary shares (2)
|
10.
|
|
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
|
11.
|
|
Percent
of Class Represented by Amount in Row (9)
26.2%(3)
|
12.
|
|
Type
of Reporting Person (See Instructions)
OO
|
|
(1)
|
This Schedule 13G is
filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-Capital GmbH & Co. KG
(“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp,
Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich
(“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-Capital, OH
Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the
“Reporting Persons”). The Reporting Persons expressly disclaim status as a “group”
for purposes of this Schedule 13G.
|
|
(2)
|
Represents
shares held of record by dievini.
|
|
(3)
|
This
percentage is calculated based on 62,908,617 shares of the Issuer’s ordinary
shares reported to be issued by the Issuer in its Form F-1 Registration Statement filed with the Securities and Exchange Commission
on July 31, 2020.
|
|
|
|
|
|
CUSIP
NO. N44445109
|
|
13
G
|
|
Page
3 of 14 Pages
|
1.
|
|
Name
of Reporting Persons
DH-Capital
GmbH & Co. KG
|
2.
|
|
Check
the Appropriate Box if a Member of a Group (See Instructions)
(a) ☐ (b) ☐
(1)
|
3.
|
|
SEC
USE ONLY
|
4.
|
|
Citizenship
or Place of Organization
Germany
|
Number
of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
|
|
5.
|
|
Sole
Voting Power
0
ordinary shares
|
|
6.
|
|
Shared
Voting Power
16,476,073
ordinary shares (2)
|
|
7.
|
|
Sole
Dispositive Power
0
ordinary shares
|
|
8.
|
|
Shared
Dispositive Power
16,476,073
ordinary shares (2)
|
9.
|
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
16,476,073
ordinary shares common shares (2)
|
10.
|
|
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
|
11.
|
|
Percent
of Class Represented by Amount in Row (9)
26.2%(3)
|
12.
|
|
Type
of Reporting Person (See Instructions)
OO
|
|
(1)
|
This
Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-Capital GmbH & Co. KG
(“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel
Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr.
Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-Capital, OH Beteiligungen, Dietmar
Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”).
The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
|
|
(2)
|
Represents
shares held of record by dievini.
|
|
(3)
|
This
percentage is calculated based on 62,908,617 shares of the Issuer’s ordinary
shares reported to be issued by the Issuer in its Form F-1 Registration Statement filed with the Securities and Exchange Commission
on July 31, 2020.
|
|
|
|
|
|
CUSIP
NO. N44445109
|
|
13
G
|
|
Page
4 of 14 Pages
|
1.
|
|
Name
of Reporting Persons
OH
Beteiligungen GmbH & Co. KG
|
2.
|
|
Check
the Appropriate Box if a Member of a Group (See Instructions)
(a) ☐ (b) ☐ (1)
|
3.
|
|
SEC
USE ONLY
|
4.
|
|
Citizenship
or Place of Organization
Germany
|
Number
of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
|
|
5.
|
|
Sole
Voting Power
0
ordinary shares
|
|
6.
|
|
Shared
Voting Power
16,476,073
ordinary shares (2)
|
|
7.
|
|
Sole
Dispositive Power
0
ordinary shares
|
|
8.
|
|
Shared
Dispositive Power
16,476,073
ordinary shares(2)
|
9.
|
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
16,476,073
ordinary shares(2)
|
10.
|
|
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
|
11.
|
|
Percent
of Class Represented by Amount in Row (9)
26.2%(3)
|
12.
|
|
Type
of Reporting Person (See Instructions)
OO
|
|
(1)
|
This
Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-Capital GmbH & Co. KG
(“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel
Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr.
Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-Capital, OH Beteiligungen, Dietmar
Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”).
The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
|
|
(2)
|
Represents
shares held of record by dievini.
|
|
(3)
|
This
percentage is calculated based on 62,908,617 shares of the Issuer’s ordinary
shares reported to be issued by the Issuer in its Form F-1 Registration Statement filed with the Securities and Exchange Commission
on July 31, 2020.
|
|
|
|
|
|
CUSIP
NO. N44445109
|
|
13
G
|
|
Page
5 of 14 Pages
|
1.
|
|
Name
of Reporting Persons
Dietmar
Hopp
|
2.
|
|
Check
the Appropriate Box if a Member of a Group (See Instructions)
(a) ☐ (b) ☐
(1)
|
3.
|
|
SEC
USE ONLY
|
4.
|
|
Citizenship
or Place of Organization
Germany
|
Number
of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
|
|
5.
|
|
Sole
Voting Power
0
ordinary shares
|
|
6.
|
|
Shared
Voting Power
16,476,073
ordinary shares (2)
|
|
7.
|
|
Sole
Dispositive Power
0
ordinary shares
|
|
8.
|
|
Shared
Dispositive Power
16,476,073
ordinary shares (2)
|
9.
|
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
16,476,073
ordinary shares(2)
|
10.
|
|
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
|
11.
|
|
Percent
of Class Represented by Amount in Row (9)
26.2%(3)
|
12.
|
|
Type
of Reporting Person (See Instructions)
IN
|
|
(1)
|
This
Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-Capital GmbH & Co. KG
(“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel
Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”),
Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp,
Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly
disclaim status as a “group” for purposes of this Schedule 13G.
|
|
(2)
|
Represents
shares held of record by dievini.
|
|
(3)
|
This
percentage is calculated based on 62,908,617 shares of the Issuer’s ordinary
shares reported to be issued by the Issuer in its Form F-1 Registration Statement filed with the Securities and Exchange Commission
on July 31, 2020.
|
|
|
|
|
|
CUSIP
NO. N44445109
|
|
13
G
|
|
Page
6 of 14 Pages
|
1.
|
|
Name
of Reporting Persons
Oliver
Hopp
|
2.
|
|
Check
the Appropriate Box if a Member of a Group (See Instructions)
(a) ☐ (b) ☐ (1)
|
3.
|
|
SEC
USE ONLY
|
4.
|
|
Citizenship
or Place of Organization
Germany
|
Number
of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
|
|
5.
|
|
Sole
Voting Power
0
ordinary shares
|
|
6.
|
|
Shared
Voting Power
16,476,073
ordinary shares (2)
|
|
7.
|
|
Sole
Dispositive Power
0
ordinary shares
|
|
8.
|
|
Shared
Dispositive Power
16,476,073
ordinary shares (2)
|
9.
|
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
16,476,073
ordinary shares(2)
|
10.
|
|
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
|
11.
|
|
Percent
of Class Represented by Amount in Row (9)
26.2%(3)
|
12.
|
|
Type
of Reporting Person (See Instructions)
IN
|
|
(1)
|
This
Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-Capital GmbH & Co. KG
(“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel
Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr.
Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-Capital, OH Beteiligungen, Dietmar
Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting
Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
|
|
(2)
|
Represents
shares held of record by dievini.
|
|
(3)
|
This
percentage is calculated based on 62,908,617 shares of the Issuer’s ordinary
shares reported to be issued by the Issuer in its Form F-1 Registration Statement filed with the Securities and Exchange Commission
on July 31, 2020.
|
|
|
|
|
|
CUSIP
NO. N44445109
|
|
13
G
|
|
Page
7 of 14 Pages
|
1.
|
|
Name
of Reporting Persons
Daniel
Hopp
|
2.
|
|
Check
the Appropriate Box if a Member of a Group (See Instructions)
(a) ☐ (b) ☐
(1)
|
3.
|
|
SEC
USE ONLY
|
4.
|
|
Citizenship
or Place of Organization
Germany
|
Number
of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
|
|
5.
|
|
Sole
Voting Power
0
ordinary shares
|
|
6.
|
|
Shared
Voting Power
16,476,073
ordinary shares (2)
|
|
7.
|
|
Sole
Dispositive Power
0
ordinary shares
|
|
8.
|
|
Shared
Dispositive Power
16,476,073
ordinary shares (2)
|
9.
|
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
16,476,073
ordinary shares (2)
|
10.
|
|
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
|
11.
|
|
Percent
of Class Represented by Amount in Row (9)
26.2%(3)
|
12.
|
|
Type
of Reporting Person (See Instructions)
IN
|
|
(1)
|
This
Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-Capital GmbH & Co. KG
(“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel
Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr.
Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-Capital, OH Beteiligungen, Dietmar
Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”).
The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
|
|
(2)
|
Represents
shares held of record by dievini.
|
|
(3)
|
This
percentage is calculated based on 62,908,617 shares of the Issuer’s ordinary
shares reported to be issued by the Issuer in its Form F-1 Registration Statement filed with the Securities and Exchange Commission
on July 31, 2020.
|
|
|
|
|
|
CUSIP
NO. N44445109
|
|
13
G
|
|
Page
8 of 14 Pages
|
1.
|
|
Name
of Reporting Persons
Prof.
Dr. Friedrich von Bohlen und Halbach
|
2.
|
|
Check
the Appropriate Box if a Member of a Group (See Instructions)
(a) ☐ (b) ☐
(1)
|
3.
|
|
SEC
USE ONLY
|
4.
|
|
Citizenship
or Place of Organization
Germany
|
Number
of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
|
|
5.
|
|
Sole
Voting Power
0
ordinary shares
|
|
6.
|
|
Shared
Voting Power
16,476,073
ordinary shares (2)
|
|
7.
|
|
Sole
Dispositive Power
0
ordinary shares
|
|
8.
|
|
Shared
Dispositive Power
16,476,073
ordinary shares (2)
|
9.
|
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
16,476,073
ordinary shares (3)
|
10.
|
|
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
|
11.
|
|
Percent
of Class Represented by Amount in Row (9)
26.2%(5)
|
12.
|
|
Type
of Reporting Person (See Instructions)
IN
|
|
(1)
|
This
Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-Capital GmbH & Co. KG
(“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel
Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”),
Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver
Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting
Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
|
|
(2)
|
Represents
shares held of record by dievini.
|
|
(5)
|
This
percentage is calculated based on 62,908,617 shares of the Issuer’s ordinary
shares reported to be issued by the Issuer in its Form F-1 Registration Statement filed with the Securities and Exchange Commission
on July 31, 2020.
|
|
|
|
|
|
CUSIP
NO. N44445109
|
|
13
G
|
|
Page
9 of 14 Pages
|
1.
|
|
Name
of Reporting Persons
Prof.
Dr. Christof Hettich
|
2.
|
|
Check
the Appropriate Box if a Member of a Group (See Instructions)
(a) ☐ (b) ☐
(1)
|
3.
|
|
SEC
USE ONLY
|
4.
|
|
Citizenship
or Place of Organization
Germany
|
Number
of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
|
|
5.
|
|
Sole
Voting Power
0
ordinary shares
|
|
6.
|
|
Shared
Voting Power
16,476,073
ordinary shares (2)
|
|
7.
|
|
Sole
Dispositive Power
0
ordinary shares
|
|
8.
|
|
Shared
Dispositive Power
16,476,073
ordinary shares (2)
|
9.
|
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
16,476,073
ordinary shares
|
10.
|
|
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
|
11.
|
|
Percent
of Class Represented by Amount in Row (9)
26.2(3)
|
12.
|
|
Type
of Reporting Person (See Instructions)
IN
|
|
(1)
|
This
Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-Capital GmbH & Co. KG
(“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel
Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr.
Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-Capital, OH Beteiligungen, Dietmar
Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”).
The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
|
|
(2)
|
Represents
shares held of record by dievini.
|
|
(3)
|
This
percentage is calculated based on 62,908,617 shares of the Issuer’s ordinary
shares reported to be issued by the Issuer in its Form F-1 Registration Statement filed with the Securities and Exchange Commission
on July 31, 2020.
|
|
|
|
|
|
CUSIP
NO. N44445109
|
|
13
G
|
|
Page
10 of 14 Pages
|
1.
|
|
Name
of Reporting Persons
Dr.
Mathias Hothum
|
2.
|
|
Check
the Appropriate Box if a Member of a Group (See Instructions)
(a) ☐ (b) ☐
(1)
|
3.
|
|
SEC
USE ONLY
|
4.
|
|
Citizenship
or Place of Organization
Germany
|
Number
of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
|
|
5.
|
|
Sole
Voting Power
0
ordinary shares
|
|
6.
|
|
Shared
Voting Power
16,476,073
ordinary shares (2)
|
|
7.
|
|
Sole
Dispositive Power
0
ordinary shares
|
|
8.
|
|
Shared
Dispositive Power
16,476,073
ordinary shares (2)
|
9.
|
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
16,476,073
ordinary shares
|
10.
|
|
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
|
11.
|
|
Percent
of Class Represented by Amount in Row (9)
26.2(3)
|
12.
|
|
Type
of Reporting Person (See Instructions)
IN
|
|
(1)
|
This
Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-Capital GmbH & Co. KG
(“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel
Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr.
Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-Capital, OH Beteiligungen, Dietmar
Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”).
The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
|
|
(2)
|
Represents
shares held of record by dievini.
|
|
(3)
|
This
percentage is calculated based on 62,908,617 shares of the Issuer’s ordinary
shares reported to be issued by the Issuer in its Form F-1 Registration Statement filed with the Securities and Exchange Commission
on July 31, 2020.
|
|
|
|
|
|
CUSIP
NO. N44445109
|
|
13
G
|
|
Page
11 of 14 Pages
|
Introductory
Note: This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-Capital GmbH &
Co. KG (“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver
Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof
Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-Capital,
OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting
Persons”) in respect of ordinary shares of Immatics N.V.
Item 1(a)
|
Name
of Issuer:
|
Immatics
N.V.
Item 1(b)
|
Address
of Issuer’s principal executive offices:
|
Paul-Ehrlich-Straße
15
72076
Tübingen, Germany
Items 2(a)
|
Name
of Reporting Persons filing:
|
dievini
Hopp BioTech holding GmbH & Co. KG (“dievini”)
DH-Capital
GmbH & Co. KG (“DH-Capital”)
OH
Beteiligungen GmbH & Co. KG (“OH Beteiligungen”)
Dietmar
Hopp
Oliver
Hopp
Daniel
Hopp
Prof.
Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”)
Prof.
Dr. Christof Hettich (“Dr. Hettich”)
Dr. Mathias
Hothum (“Dr. Hothum”)
Item 2(b)
|
Address
or principal business office or, if none, residence:
|
The
address of the principal business office of dievini, Dietmar Hopp, Dr. von Bohlen, Dr. Hettich and Dr. Hothum is
c/o dievini Hopp BioTech holding GmbH & Co. KG, Johann-Jakob-Astor Straße 57, 69190 Walldorf, Germany.
The
address of the principal business office of DH-Capital GmbH & Co. KG and OH Beteiligungen GmbH & Co. KG is Opelstraße
28, 68789 St. Leon-Rot, Germany.
The
address of the principal business office of Oliver Hopp is Johann-Jakob-Astor-Straße 59, 69190 Walldorf, Germany.
The
address of the principal business office of Daniel Hopp is Johann-Jakob-Astor-Straße 59, 69190 Walldorf, Germany.
Name
|
|
Citizenship or Place of Organization
|
Dievini
|
|
Germany
|
DH-Capital
|
|
Germany
|
OH Beteiligungen
|
|
Germany
|
Dietmar Hopp
|
|
Germany
|
Oliver
Hopp
|
|
Germany
|
Daniel
Hopp
|
|
Germany
|
Dr. von
Bohlen
|
|
Germany
|
Dr. Hettich
|
|
Germany
|
Dr. Hothum
|
|
Germany
|
|
|
|
|
|
CUSIP
NO. N44445109
|
|
13
G
|
|
Page
12 of 14 Pages
|
Item 2(d)
|
Title
of class of securities:
|
Ordinary
shares, nominal value €0.01 per share.
N44445109
Item 3
|
If
this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filings is
a:
|
Not
applicable.
The
following information with respect to the ownership of ordinary shares of the Issuer by the Reporting Persons filing this statement
on Schedule 13G is provided as of December 31, 2020.
Reporting Persons
|
|
Common Shares Held Directly
|
|
|
Sole Voting Power
|
|
|
Shared Voting Power
|
|
|
Sole Dispositive Power
|
|
|
Shared Dispositive Power
|
|
|
Beneficial Ownership
|
|
|
Percentage of Class(1)
|
|
dievini Hopp BioTech holding GmbH & Co. KG(2)
|
|
|
16,476,073
|
|
|
|
0
|
|
|
|
16,476,073
|
|
|
|
0
|
|
|
|
16,476,073
|
|
|
|
16,476,073
|
|
|
|
26.2
|
%
|
DH-Capital GmbH & Co. KG(3)
|
|
|
0
|
|
|
|
0
|
|
|
|
16,476,073
|
|
|
|
0
|
|
|
|
16,476,073
|
|
|
|
16,476,073
|
|
|
|
26.2
|
%
|
OH Beteiligungen GmbH & Co. KG(3)
|
|
|
0
|
|
|
|
0
|
|
|
|
16,476,073
|
|
|
|
0
|
|
|
|
16,476,073
|
|
|
|
16,476,073
|
|
|
|
26.2
|
%
|
Dietmar Hopp(3)(4)
|
|
|
0
|
|
|
|
0
|
|
|
|
16,476,073
|
|
|
|
0
|
|
|
|
16,476,073
|
|
|
|
16,476,073
|
|
|
|
26.2
|
%
|
Oliver Hopp(3)
|
|
|
0
|
|
|
|
0
|
|
|
|
16,476,073
|
|
|
|
0
|
|
|
|
16,476,073
|
|
|
|
16,476,073
|
|
|
|
26.2
|
%
|
Daniel Hopp(3)
|
|
|
0
|
|
|
|
0
|
|
|
|
16,476,073
|
|
|
|
0
|
|
|
|
16,476,073
|
|
|
|
16,476,073
|
|
|
|
26.2
|
%
|
Prof. Dr. Friedrich von Bohlen und Halbach(3)(4)
|
|
|
0
|
|
|
|
0
|
|
|
|
16,476,073
|
|
|
|
0
|
|
|
|
16,476,073
|
|
|
|
16,476,073
|
|
|
|
26.2
|
%
|
Prof. Dr. Christof Hettich(3)(4)
|
|
|
0
|
|
|
|
0
|
|
|
|
16,476,073
|
|
|
|
0
|
|
|
|
16,476,073
|
|
|
|
16,476,073
|
|
|
|
26.2
|
%
|
Dr. Mathias Hothum(4)
|
|
|
0
|
|
|
|
0
|
|
|
|
16,476,073
|
|
|
|
0
|
|
|
|
16,476,073
|
|
|
|
16,476,073
|
|
|
|
26.2
|
%
|
|
(1)
|
This
percentage is calculated based on 62,908,617 shares of the Issuer’s ordinary
shares reported to be issued by the Issuer in its Form F-1 Registration Statement filed with the Securities and Exchange Commission
on July 31, 2020
|
|
(2)
|
16,476,073
ordinary shares of the Issuer are held of record by dievini.
|
|
(3)
|
DH-Capital,
OH Beteiligungen, Dr. von Bohlen and Dr. Hettich are collectively the holders of 100% of the limited partner interest
in dievini. DH-Capital and OH Beteiligungen each hold a 40% limited partner interest in dievini and therefore, control the voting
and dispositive decisions of dievini together and may be deemed to beneficially own the shares held by dievini. Dietmar Hopp,
Daniel Hopp and Oliver Hopp are the ultimate controlling persons of dievini, DH-Capital and OH Beteiligungen, and control the
voting and investment decisions of the ultimate parent company of dievini and therefore, may be deemed to beneficially own the
shares held by dievini by virtue of their status as controlling persons of dievini.
|
|
(4)
|
The
sole general partner of dievini with the authorization to represent is dievini Verwaltungs GmbH; however, 100% of the shares of
dievini Verwaltungs GmbH are held by dievini so dievini Verwaltungs GmbH is not considered to have control over dievini. The managing
directors of dievini Verwaltungs GmbH are Dietmar Hopp, Dr. von Bohlen, Dr. Hettich and Dr. Hothum. Voting and
dispositive decisions made within dievini Verwaltungs GmbH regarding the securities held by dievini are made by at least two managing
directors acting together; however, Dietmar Hopp is entitled to represent dievini Verwaltungs GmbH solely. Therefore, in their
capacity as managing directors, Dietmar Hopp, Dr. von Bohlen, Dr. Hettich and Dr. Hothum share voting and dispositive
power over the shares held by dievini, and may be deemed to beneficially own such shares held by dievini; however, each of Dietmar
Hopp, Dr. von Bohlen, Dr. Hettich and Dr. Hothum disclaims beneficial ownership of the shares held by dievini except
to the extent of their pecuniary interests therein.
|
|
|
|
|
|
CUSIP
NO. N44445109
|
|
13
G
|
|
Page
13 of 14 Pages
|
Item 5
|
Ownership
of Five Percent or Less of a Class
|
If
this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities, check the following: ☐
Item 6
|
Ownership
of More than Five Percent on Behalf of Another Person
|
Not
applicable.
Item 7
|
Identification
and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control
Person
|
Not
applicable.
Item 8
|
Identification
and Classification of Members of the Group
|
Not
applicable.
Item 9
|
Notice
of Dissolution of Group
|
Not
applicable.
Not
applicable.
|
|
|
|
|
CUSIP
NO. N44445109
|
|
13
G
|
|
Page
14 of 14 Pages
|
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated:
February 11, 2021
|
DIEVINI
HOPP BIOTECH HOLDING GMBH & CO. KG
|
|
|
|
|
By:
|
dievini
Verwaltungs GmbH
|
|
|
its
General Partner
|
|
|
|
|
By:
|
/s/
Dr. Marc Hauser
|
|
|
Name:
|
Dr. Marc
Hauser
|
|
|
Title:
|
Attorney-in-fact
|
|
|
|
DH-CAPITAL
GMBH & CO. KG
|
|
|
|
|
By:
|
DH
Verwaltungs GmbH
|
|
|
its
General Partner
|
|
|
|
|
By:
|
/s/
Dr. Marc Hauser
|
|
|
Name:
|
Dr. Marc
Hauser
|
|
|
Title:
|
Attorney-in-fact
|
|
|
|
OH
BETEILIGUNGEN GMBH & CO. KG
|
|
|
|
|
By:
|
OH
Verwaltungs GmbH
|
|
|
its
General Partner
|
|
|
|
|
By:
|
/s/
Dr. Marc Hauser
|
|
|
Name:
|
Dr. Marc
Hauser
|
|
|
Title:
|
Attorney-in-fact
|
|
/s/
Dr. Marc Hauser as attorney-in-fact
|
|
DIETMAR
HOPP
|
|
|
|
/s/
Dr. Marc Hauser as attorney-in-fact
|
|
OLIVER
HOPP
|
|
|
|
/s/
Dr. Marc Hauser as attorney-in-fact
|
|
DANIEL
HOPP
|
|
|
|
/s/
Dr. Marc Hauser as attorney-in-fact
|
|
FRIEDRICH
VON BOHLEN UND HALBACH
|
|
|
|
/s/
Dr. Marc Hauser as attorney-in-fact
|
|
CHRISTOF
HETTICH
|
|
|
|
/s/
Dr. Marc Hauser as attorney-in-fact
|
|
MATHIAS
HOTHUM
|
Exhibit(s):
1
– Power of Attorney
2
– Joint Filing Statement
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Mar 2023 to Mar 2024